JAC Advance Access originally published online on December 14, 2005
Journal of Antimicrobial Chemotherapy 2006 57(2):344-348; doi:10.1093/jac/dki446
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Effect of 1-(1-naphthylmethyl)-piperazine, a novel putative efflux pump inhibitor, on antimicrobial drug susceptibility in clinical isolates of Enterobacteriaceae other than Escherichia coli
1 Center for Infectious Diseases and Travel Medicine, Department of Medicine, University Hospital, Freiburg, Germany; 2 Section of Infectious Diseases, Hacettepe University, Ankara, Turkey; 3 Institute of Environmental Medicine and Hospital Epidemiology, University Hospital, Freiburg, Germany
Received 30 August 2005; returned 28 October 2005; revised 2 November 2005; accepted 11 November 2005
* Correspondence address. Medizinische Universitätsklinik, Hugstetter Strasse 55, D-79106 Freiburg, Germany. Tel: +49-761-270-1819; Fax: +49-761-270-1820; E-mail: kern{at}if-freiburg.de
Objectives: 1-(1-Naphthylmethyl)-piperazine (NMP) has been shown to reverse multidrug resistance (MDR) in Escherichia coli overexpressing RND type efflux pumps, but there is no data on its activity in Enterobacteriaceae other than E. coli.
Methods: The antimicrobial susceptibilities of laboratory strains and 167 clinical isolates of Enterobacteriaceae to a variety of antimicrobial agents were determined in the absence and presence of NMP and, for comparison, of Phe-Arg-ß-naphthylamide (PAßN), another putative efflux pump inhibitor (EPI). A 4-fold or greater reduction of the MIC after EPI addition was considered significant.
Results: NMP consistently reduced the MIC of linezolid in Citrobacter freundii, Enterobacter aerogenes and Klebsiella pneumoniae clinical isolates. Significant effects of NMP addition in >50% of tested isolates were also seen for levofloxacin, tetracycline and chloramphenicol in E. aerogenes, and for levofloxacin and tetracycline in K. pneumoniae, whereas no or minor effects were observed in Serratia marcescens. MDR reversal by NMP was more likely in isolates with decreased susceptibility to fluoroquinolones. In most fluoroquinolone-resistant strains the activity was sufficient to render isolates drug-susceptible at clinically achievable concentrations. The activity of PAßN was different from that of NMP, suggesting different modes of action of the two putative EPIs.
Conclusion: NMP has moderate activity in reversing MDR in many but not all members of the Enterobacteriaceae family including clinical isolates. Its effects on resistance reversal depend on bacterial species and drug, and are different from those seen with PAßN.
Keywords: multidrug resistance , fluoroquinolones , nosocomial pathogens
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Chusri, I. Villanueva, S. P. Voravuthikunchai, and J. Davies Enhancing antibiotic activity: a strategy to control Acinetobacter infections J. Antimicrob. Chemother., December 1, 2009; 64(6): 1203 - 1211. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Bratu, D. Landman, A. George, J. Salvani, and J. Quale Correlation of the expression of acrB and the regulatory genes marA, soxS and ramA with antimicrobial resistance in clinical isolates of Klebsiella pneumoniae endemic to New York City J. Antimicrob. Chemother., August 1, 2009; 64(2): 278 - 283. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hannula and M.-L. Hanninen Effect of putative efflux pump inhibitors and inducers on the antimicrobial susceptibility of Campylobacter jejuni and Campylobacter coli J. Med. Microbiol., July 1, 2008; 57(7): 851 - 855. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Schumacher, R. Trittler, J. A. Bohnert, K. Kummerer, J.-M. Pages, and W. V. Kern Intracellular accumulation of linezolid in Escherichia coli, Citrobacter freundii and Enterobacter aerogenes: role of enhanced efflux pump activity and inactivation J. Antimicrob. Chemother., June 1, 2007; 59(6): 1261 - 1264. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Mahamoud, J. Chevalier, S. Alibert-Franco, W. V. Kern, and J.-M. Pages Antibiotic efflux pumps in Gram-negative bacteria: the inhibitor response strategy J. Antimicrob. Chemother., June 1, 2007; 59(6): 1223 - 1229. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Pannek, P. G. Higgins, P. Steinke, D. Jonas, M. Akova, J. A. Bohnert, H. Seifert, and W. V. Kern Multidrug efflux inhibition in Acinetobacter baumannii: comparison between 1-(1-naphthylmethyl)-piperazine and phenyl-arginine-{beta}-naphthylamide J. Antimicrob. Chemother., May 1, 2006; 57(5): 970 - 974. [Abstract] [Full Text] [PDF]
|
|